Publication | Closed Access
Early Impact of Nirsevimab on Ambulatory All-Cause Bronchiolitis: A Prospective Multicentric Surveillance Study in France
16
Citations
6
References
2024
Year
AsthmaPulmonary CarePediatric Lung DiseaseAll-cause BronchiolitisPediatric EpidemiologyClinical EpidemiologyRespiratory InfectionPublic HealthRespiratory DiseasesEarly ImpactPulmonary MedicineLung CancerEpidemiologyPulmonary DiseaseAmbulatory All-cause BronchiolitisLowest NumberGlobal HealthPediatricsInfectious Respiratory DiseaseBronchiolitis CasesMedicine
After the implementation of nirsevimab in 2023 in France as compared with 2022–2023, we found a 52.7%, (95% CI [46.4–58.9])decrease in all-cause bronchiolitis in children <3 months with the lowest number of bronchiolitis cases in this population since 2017.
| Year | Citations | |
|---|---|---|
Page 1
Page 1